

Interaction Report

Report ID: 1
Date Produced: 22 January 2021

Antiretroviral Treatment

Co-medications

Abacavir (ABC)	Grapefruit juice
Albuvirtide (ABT)	
Atazanavir + ritonavir (ATV/r)	
Atazanavir alone (ATV)	
Atazanavir/cobicistat (ATV/c)	
Bictegravir/ Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF)	
Cabotegravir [oral] (CAB oral)	
Cabotegravir/rilpivirine [long acting] (CAB/RPV LA)	
Darunavir + ritonavir (DRV/r)	
Darunavir/cobicistat (DRV/c)	
Darunavir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (DRV/c/FTC/TAF)	
Didanosine (ddl)	
Dolutegravir (DTG)	
Dolutegravir/Abacavir/ Lamivudine (DTG/ABC/3TC)	
Dolutegravir/Lamivudine (DTG/3TC)	
Dolutegravir/Rilpivirine (DTG/RPV)	
Doravirine (DOR)	
Doravirine/Lamivudine/ Tenofovir-DF (DOR/3TC/TDF)	
Efavirenz (EFV)	
Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (EVG/c/FTC/TAF)	
Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir-DF (EVG/c/FTC/TDF)	
Emtricitabine (FTC)	
Emtricitabine/Tenofovir alafenamide (FTC/TAF, PrEP)	
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)	
Etravirine (ETR)	
Fosamprenavir (FPV)	
Fostemsavir (FTR)	
Ibalizumab-uiyk (IBA)	
Indinavir (IDV)	
Lamivudine (3TC)	
Lopinavir (LPV)	
Maraviroc (MVC)	
Nevirapine (NVP)	
Raltegravir (RAL)	
Rilpivirine (RPV)	
Rilpivirine/ Emtricitabine/Tenofovir alafenamide (RPV/FTC/TAF)	
Ritonavir (RTV)	
Saquinavir (SQV)	
Stavudine (d4T)	
Tenofovir-DF (TDF)	
Tipranavir (TPV)	
Zidovudine (AZT/ZDV)	

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see www.hiv-druginteractions.org.

Description of the interactions

Potential weak interaction - additional action/monitoring or dosage adjustment is unlikely to be required (YELLOW)

Maraviroc (MVC) + Grapefruit juice

Coadministration has not been studied but may increase in maraviroc concentrations through inhibition of CYP3A4 and possibly P-glycoprotein. The magnitude of the potential interaction is difficult to predict as the effect of grapefruit juice is concentration, dose and preparation dependent and varies widely across brands, but as grapefruit juice inhibits intestinal CYP3A4 and maraviroc has a moderate intestinal extraction, the interaction is likely to be modest.

Doravirine/Lamivudine/ Tenofovir-DF (DOR/3TC/TDF) + Grapefruit juice

Coadministration has not been studied but may increase doravirine concentrations through inhibition of CYP3A4. No dose adjustment of doravirine is required as phase I trials showed a good tolerability of doravirine with up to a 3-4 fold increase in exposure. Lamivudine and tenofovir-DF are unlikely to be impacted by grapefruit juice.

Doravirine (DOR) + Grapefruit juice

Coadministration has not been studied but may increase doravirine concentrations through inhibition of CYP3A4. No dose adjustment of doravirine is required as phase I trials showed a good tolerability of doravirine with up to a 3-4 fold increase in exposure.

No clinically significant interaction expected (GREEN)

Efavirenz (EFV) + Grapefruit juice

Nevirapine (NVP) + Grapefruit juice

Indinavir (IDV) + Grapefruit juice

Ritonavir (RTV) + Grapefruit juice

Saquinavir (SQV) + Grapefruit juice

Lopinavir (LPV) + Grapefruit juice

Tipranavir (TPV) + Grapefruit juice

Fosamprenavir (FPV) + Grapefruit juice

Etravirine (ETR) + Grapefruit juice

Zidovudine (AZT/ZDV) + Grapefruit juice

Tenofovir-DF (TDF) + Grapefruit juice

Stavudine (d4T) + Grapefruit juice

Raltegravir (RAL) + Grapefruit juice

Lamivudine (3TC) + Grapefruit juice

Emtricitabine (FTC) + Grapefruit juice

Didanosine (ddI) + Grapefruit juice

Abacavir (ABC) + Grapefruit juice

Rilpivirine (RPV) + Grapefruit juice

Dolutegravir (DTG) + Grapefruit juice

Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (EVG/c/FTC/TAF) + Grapefruit juice

Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir-DF (EVG/c/FTC/TDF) + Grapefruit juice
Emtricitabine/Tenofovir alafenamide (FTC/TAF, PrEP) + Grapefruit juice
Rilpivirine/ Emtricitabine/Tenofovir alafenamide (RPV/FTC/TAF) + Grapefruit juice
Bictegravir/ Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF) + Grapefruit juice
Ibalizumab-uiyk (IBA) + Grapefruit juice
Darunavir/cobicistat (DRV/c) + Grapefruit juice
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) + Grapefruit juice
Darunavir + ritonavir (DRV/r) + Grapefruit juice
Darunavir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (DRV/c/FTC/TAF) + Grapefruit juice
Dolutegravir/Rilpivirine (DTG/RPV) + Grapefruit juice
Atazanavir/cobicistat (ATV/c) + Grapefruit juice
Atazanavir alone (ATV) + Grapefruit juice
Atazanavir + ritonavir (ATV/r) + Grapefruit juice
Dolutegravir/Lamivudine (DTG/3TC) + Grapefruit juice
Dolutegravir/Abacavir/ Lamivudine (DTG/ABC/3TC) + Grapefruit juice
Albuvirtide (ABT) + Grapefruit juice
Cabotegravir/rilpivirine [long acting] (CAB/RPV LA) + Grapefruit juice
Cabotegravir [oral] (CAB oral) + Grapefruit juice
Fostemsavir (FTR) + Grapefruit juice